189 related articles for article (PubMed ID: 7903681)
1. Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival.
Qin L; Chavin KD; Lin J; Yagita H; Bromberg JS
J Exp Med; 1994 Jan; 179(1):341-6. PubMed ID: 7903681
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD2 and anti-CD3 monoclonal antibodies synergize to prolong allograft survival with decreased side effects.
Chavin KD; Qin L; Lin J; Kaplan AJ; Bromberg JS
Transplantation; 1993 Apr; 55(4):901-8. PubMed ID: 8097344
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD2 monoclonal antibodies synergize with FK506 but not with cyclosporine or rapamycin to induce tolerance.
Chavin KD; Qin L; Woodward JE; Lin J; Bromberg JS
Transplantation; 1994 Mar; 57(5):736-40. PubMed ID: 7511258
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD48 (murine CD2 ligand) mAbs suppress cell mediated immunity in vivo.
Chavin KD; Qin L; Lin J; Woodward J; Baliga P; Kato K; Yagita H; Bromberg JS
Int Immunol; 1994 May; 6(5):701-9. PubMed ID: 7521667
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD2 monoclonal antibodies synergize with anti-CD3 to prolong allograft survival and decrease cytokine production.
Chavin KD; Qin L; Lin J; Kaplan AJ; Bromberg JS
Transplant Proc; 1993 Feb; 25(1 Pt 1):823-4. PubMed ID: 8094913
[No Abstract] [Full Text] [Related]
6. Combined anti-CD2 and anti-CD3 receptor monoclonal antibodies induce donor-specific tolerance in a cardiac transplant model.
Chavin KD; Qin L; Lin J; Yagita H; Bromberg JS
J Immunol; 1993 Dec; 151(12):7249-59. PubMed ID: 7903105
[TBL] [Abstract][Full Text] [Related]
7. Prolongation of allograft and xenograft survival in mice by anti-CD2 monoclonal antibodies.
Chavin KD; Lau HT; Bromberg JS
Transplantation; 1992 Aug; 54(2):286-91. PubMed ID: 1353913
[TBL] [Abstract][Full Text] [Related]
8. Modulation of the CD2 receptor and not disruption of the CD2/CD48 interaction is the principal action of CD2-mediated immunosuppression in the rat.
Sido B; Otto G; Zimmermann R; Müller P; Meuer SC; Dengler TJ
Cell Immunol; 1997 Nov; 182(1):57-67. PubMed ID: 9427810
[TBL] [Abstract][Full Text] [Related]
9. Prolonged allograft survival by the inhibition of costimulatory CD2 signals but not by modulation of CD48 (CD2 ligand) in the rat.
Sido B; Otto G; Zimmermann R; Müller P; Meuer S; Dengler TJ
Transpl Int; 1996; 9 Suppl 1():S323-7. PubMed ID: 8959856
[TBL] [Abstract][Full Text] [Related]
10. CD2 is a dominant target for allogeneic responses.
Bai Y; Fu S; Honig S; Wang Y; Qin L; Chen D; Bromberg JS
Am J Transplant; 2002 Aug; 2(7):618-26. PubMed ID: 12201362
[TBL] [Abstract][Full Text] [Related]
11. CTLA4-Ig abrogates the anti-globulin response and prolongs cardiac allograft survival after anti-CD2 treatment.
Stell D; Marshall H; Bradley JA; Bolton EM
Transpl Immunol; 2003; 12(1):1-7. PubMed ID: 14551027
[TBL] [Abstract][Full Text] [Related]
12. CD2-CD48 interactions promote cytotoxic T lymphocyte induction and function: anti-CD2 and anti-CD48 antibodies impair cytokine synthesis, proliferation, target recognition/adhesion, and cytotoxicity.
Musgrave BL; Watson CL; Hoskin DW
J Interferon Cytokine Res; 2003 Feb; 23(2):67-81. PubMed ID: 12744772
[TBL] [Abstract][Full Text] [Related]
13. Combination anti-CD2 and anti-CD3 monoclonal antibodies induce tolerance while altering interleukin-2, interleukin-4, tumor necrosis factor, and transforming growth factor-beta production.
Chavin KD; Qin L; Lin J; Woodward JE; Baliga P; Bromberg JS
Ann Surg; 1993 Oct; 218(4):492-501; discussion 501-3. PubMed ID: 8215640
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD2 monoclonal antibodies alter cell-mediated immunity in vivo.
Bromberg JS; Chavin KD; Altevogt P; Kyewski BA; Guckel B; Naji A; Barker CF
Transplantation; 1991 Jan; 51(1):219-25. PubMed ID: 1670971
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies against human T cell adhesion molecules--modulation of immune function in nonhuman primates.
Berlin PJ; Bacher JD; Sharrow SO; Gonzalez C; Gress RE
Transplantation; 1992 Apr; 53(4):840-9. PubMed ID: 1348883
[TBL] [Abstract][Full Text] [Related]
16. A potential immunosuppressive effect of anti-lymphocyte function-associated antigen-1 monoclonal antibody on islet transplantation.
Gotoh M; Fukuzaki T; Monden M; Dono K; Kanai T; Yagita H; Okumura K; Mori T
Transplantation; 1994 Jan; 57(1):123-6. PubMed ID: 7904780
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD2 mAbs suppress cytotoxic lymphocyte activity by the generation of Th2 suppressor cells and receptor blockade.
Chavin KD; Qin L; Yon R; Lin J; Yagita H; Bromberg JS
J Immunol; 1994 Apr; 152(8):3729-39. PubMed ID: 7908306
[TBL] [Abstract][Full Text] [Related]
18. CD48 is a counter-receptor for mouse CD2 and is involved in T cell activation.
Kato K; Koyanagi M; Okada H; Takanashi T; Wong YW; Williams AF; Okumura K; Yagita H
J Exp Med; 1992 Nov; 176(5):1241-9. PubMed ID: 1383383
[TBL] [Abstract][Full Text] [Related]
19. Induction of immunologic tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator and cytotoxic T-lymphocyte antigen 4 pathway.
Kosuge H; Suzuki J; Gotoh R; Koga N; Ito H; Isobe M; Inobe M; Uede T
Transplantation; 2003 Apr; 75(8):1374-9. PubMed ID: 12717233
[TBL] [Abstract][Full Text] [Related]
20. CD3 and CD2 ligation alters CD49d epitope expression.
Lin J; Qin L; Chavin KD; Ding Y; Punch JD; Yang Q; Burkly LC; Bromberg JS
Pathobiology; 1995; 63(3):119-32. PubMed ID: 8821628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
